Cho-Kai Wu1, Jen-Kuang Lee2, Lian-Yu Lin3, Yin-Tsen Huang4, Juey-Jen Hwang3, Chunn-Lee Lin3, Chuen-Den Tseng3, Fu-Tien Chiang3. 1. Department of Internal Medicine, National Taiwan University College of Medicine and Hospital;; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei; 2. Department of Clinical Pathology & Cardiovascular Center; 3. Department of Internal Medicine, National Taiwan University College of Medicine and Hospital; 4. Department of Family Medicine and Health Management Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
Abstract
OBJECTIVES: The objective of this study was to evaluate the renin-angiotensin system genetic effects and pharmacogenetic interactions for angiotensin-converting enzyme (ACE) inhibitors in hypertensive coronary artery disease (CAD) patients. METHODS: Subjects with hypertension and angiographic CAD were recruited from 1995 to 2003. Baseline characteristics and genetic polymorphisms [ACE gene insertion/deletion (I/D) polymorphism, six polymorphisms of the angiotensinogen (AGT) gene, and A1166C polymorphisms of the angiotensin II type I receptor gene (AGT1R)] were collected. Patients were assigned to 2 groups (ACE inhibitor or No-ACE inhibitor) and followed-for up to 12 years. Kaplan-Meier curves and Cox regression models were used to demonstrate the survival and major cardiovascular events (MACE) event-free survival trends. Pharmacogenetic effects were determined by several Cox regression models. RESULTS: Of the 518 patients in our study, 290 were treated with ACE inhibitors and 228 were not. Prescription of ACE inhibitors was associated with a lower rate of MACE at 4000 days. In addition, ACE I/D gene D was associated with a higher rate of MACE in a multivariate regression analysis [hazard ration (HR): 1.64, 95% confidence interval (CI): 1.27-1.98, p < 0.001]. This effect could be attenuated by the pharmacogenetic interaction of ACE inhibitors and the ACE gene (ACE in hibitors*ACE D gene, HR: 0.68, 95% CI: 0.52-0.84, p = 0.014). CONCLUSIONS: The use of ACE inhibitors was associated with a significant decrease in MACE in hypertensive patients diagnosed with CAD. Genetic variants were also associated with event-free survival, but their effects were modified by the use of ACE inhibitors. KEY WORDS: Angiotensin-converting enzyme inhibitors; Coronary artery disease; Hypertension; Pharmacogenetic.
OBJECTIVES: The objective of this study was to evaluate the renin-angiotensin system genetic effects and pharmacogenetic interactions for angiotensin-converting enzyme (ACE) inhibitors in hypertensive coronary artery disease (CAD) patients. METHODS: Subjects with hypertension and angiographic CAD were recruited from 1995 to 2003. Baseline characteristics and genetic polymorphisms [ACE gene insertion/deletion (I/D) polymorphism, six polymorphisms of the angiotensinogen (AGT) gene, and A1166C polymorphisms of the angiotensin II type I receptor gene (AGT1R)] were collected. Patients were assigned to 2 groups (ACE inhibitor or No-ACE inhibitor) and followed-for up to 12 years. Kaplan-Meier curves and Cox regression models were used to demonstrate the survival and major cardiovascular events (MACE) event-free survival trends. Pharmacogenetic effects were determined by several Cox regression models. RESULTS: Of the 518 patients in our study, 290 were treated with ACE inhibitors and 228 were not. Prescription of ACE inhibitors was associated with a lower rate of MACE at 4000 days. In addition, ACE I/D gene D was associated with a higher rate of MACE in a multivariate regression analysis [hazard ration (HR): 1.64, 95% confidence interval (CI): 1.27-1.98, p < 0.001]. This effect could be attenuated by the pharmacogenetic interaction of ACE inhibitors and the ACE gene (ACE in hibitors*ACE D gene, HR: 0.68, 95% CI: 0.52-0.84, p = 0.014). CONCLUSIONS: The use of ACE inhibitors was associated with a significant decrease in MACE in hypertensivepatients diagnosed with CAD. Genetic variants were also associated with event-free survival, but their effects were modified by the use of ACE inhibitors. KEY WORDS: Angiotensin-converting enzyme inhibitors; Coronary artery disease; Hypertension; Pharmacogenetic.
Authors: Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; R Scott Wright; Sidney C Smith; Alice K Jacobs; Jonathan L Halperin; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel Journal: Circulation Date: 2007-08-06 Impact factor: 29.690
Authors: S P Friedrich; B H Lorell; M F Rousseau; W Hayashida; O M Hess; P S Douglas; S Gordon; C S Keighley; C Benedict; H P Krayenbuehl Journal: Circulation Date: 1994-12 Impact factor: 29.690
Authors: Vincenza Snow; Patricia Barry; Stephan D Fihn; Raymond J Gibbons; Douglas K Owens; Sankey V Williams; Christel Mottur-Pilson; Kevin B Weiss Journal: Ann Intern Med Date: 2004-10-05 Impact factor: 25.391
Authors: Willem J Remme; Jaap W Deckers; Kim M Fox; Roberto Ferrari; Michel Bertrand; Maarten L Simoons Journal: Cardiovasc Drugs Ther Date: 2008-10-18 Impact factor: 3.727
Authors: Oana Mocan; Elena Buzdugan; Angela Cozma; Daniel Corneliu Leucuta; Dan Radulescu; Lucia Maria Procopciuc Journal: In Vivo Date: 2020 Sep-Oct Impact factor: 2.155